📰 BloombergBloombergCodex · 实盘不做把握 6/10
北京时间·🕒 发布 19:01:15时区推断·⟳ 抓取 19:12:37·⚡ 决策 07-22 19:14:57 +2m20s·97.0 天前
强生Ottava软组织手术机器人获FDA首个美国上市许可
强生（JNJ.US）获得Ottava软组织手术机器人首个美国监管许可，方向上利好其MedTech机器人业务，但初始适应症仅限部分上腹部手术，短期收入贡献相对其约千亿美元年销售基数难以量化。
📄 原文Bloomberg↗ 原文
After more than a decade of research and years of delays, Johnson & Johnson now has a robot on the market for soft tiss…
不做 强生（JNJ.US）
Ottava获FDA许可方向正面，但强生是超大市值综合药械公司，本次未披露订单、定价、装机或收入指引；从1010亿美元级年收入基数看，短线业绩增量无法量化，且1月提交和5月临床数据已提前铺垫，不做。
不做 直觉外科（ISRG.US）
强生获批对ISRG是竞争利空，但生态迁移和装机替代偏多年维度，且ISRG已在数日前因增长和竞争担忧大跌；未确认可借券且看空催化强度不足以追空，不做。
不做 美敦力（MDT.US）
美敦力Hugo同在手术机器人赛道，但强生获批对其既非明确利好也非直接利空，缺少可执行同向交易边界，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 强生已宣布向FDA提交Ottava De Novo申请，并说明目标适应症为上腹部普通外科多类手术，本次许可有明确前置信号。
- 强生披露30例FORTE临床研究达到安全和性能终点，且所有胃旁路手术均由Ottava完成，为FDA申请提供临床依据。
- Bloomberg报道Ottava获得FDA首个美国监管许可，许可覆盖部分上腹部手术，包括胃旁路和食管裂孔疝修复。市场反应:信号到达时美股仍为盘前，不适合用连续盘中成交确认。
关键理由
- 强生（JNJ.US）获得Ottava软组织手术机器人首个美国监管许可，方向上利好其MedTech机器人业务，但初始适应症仅限部分上腹部手术，短期收入贡献相对其约千亿美元年销售基数难以量化。
- 直觉外科（ISRG.US）面临新增大厂竞争者，但da Vinci全球装机超过万台、生态和培训壁垒深，竞争传导更偏中长期，且ISRG刚因Q2指引和竞争担忧大跌，事件单独不足以追空。
- 该许可此前已有1月提交、5月临床数据披露作为明确前置信号，本次是重要里程碑但不是完全意外的新业务落地。
主要风险
- 若强生后续披露商业化时间表、定价、订单或医院装机速度超预期，JNJ/ISRG的短线重定价可能重新打开。
- ISRG近期已因增长放缓和竞争担忧大幅下跌，继续做空容易把已交易的风险重复计算。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-22 · 影响 weakens
未找到伴随获批披露的订单、定价、装机目标或短期收入指引，削弱对强生主标的的短线做多量级。
检索:Johnson & Johnson Ottava FDA approval revenue commercialization orders pricing hospitals 原文 ↗ - 做空前查反向 · 来源 web · 日期 2023-03-24 · 影响 weakens
分析认为ISRG的硬件、软件、培训和服务生态使竞争者需要多年才能形成实质份额压力，削弱用单一许可事件开空ISRG。
检索:Intuitive Surgical JNJ Ottava competition moat years analysts 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-07-18 · 影响 weakens
ISRG在本事件前数日已因增长放缓和竞争担忧大跌，继续追空存在较高price-in风险。
检索:ISRG stock fell 14 competition growth concerns July 2026 原文 ↗
原文全文
展开原文 · 2,301 字
After more than a decade of research and years of delays, Johnson & Johnson now has a robot on the market for soft tissue surgery.
The company received its first US regulatory authorization for the robotic Ottava device, according to a release on Wednesday, a move that could give it a foothold into one of the fastest-growing areas of the surgery market.
The Food and Drug Administration cleared Ottava for certain upper abdominal procedures, including gastric bypass and hiatal hernia repair. The regulatory nod followed a 30-person trial that showed that complex gastric bypass operations could be done successfully with the robot in all cases.
It’s a big moment for J&J, which has spent billions since 2015 developing and acquiring robotic technology that could compete with Intuitive Surgical Inc.’s market-leading Da Vinci system.
While J&J already sells robotic systems for procedures such as bronchoscopies, it’s a latecomer to such devices for soft tissue, a category encompassing some of the most common operations, including hernia, gallbladder and hysterectomy surgeries.
Intuitive Surgical, which brought its first robot to the market in 2000, dominates the field with more than 11,000 systems installed around the world. More recent entrants include Medtronic Plc, whose Hugo robot was cleared for urologic surgery in the US in 2025, and UK-based CMR Surgical, maker of a device that received its first US authorization for gallbladder operations in 2024.
J&J says Ottava takes up 30% to 50% less space than other systems. Instead of developing a device that must be positioned next to the patient, it built four robotic arms directly into the operating table. They fold down under the table when not in use.
“The table is a robot and the robot is a table,” said Rocco De Bernardis, J&J’s global president for Ottava and MedTech, during an exclusive demonstration of the device for Bloomberg at the company’s Santa Clara, California, office. “There is nothing else like this on the market.”
While the initial clearance is limited to upper abdominal operations, J&J executives said they have designed the Ottava device to be capable of performing all the major types of procedures that robotic surgery is used for today. Another trial in groin hernia surgery is currently ongoing.
The company received its first US regulatory authorization for the robotic Ottava device, according to a release on Wednesday, a move that could give it a foothold into one of the fastest-growing areas of the surgery market.
The Food and Drug Administration cleared Ottava for certain upper abdominal procedures, including gastric bypass and hiatal hernia repair. The regulatory nod followed a 30-person trial that showed that complex gastric bypass operations could be done successfully with the robot in all cases.
It’s a big moment for J&J, which has spent billions since 2015 developing and acquiring robotic technology that could compete with Intuitive Surgical Inc.’s market-leading Da Vinci system.
While J&J already sells robotic systems for procedures such as bronchoscopies, it’s a latecomer to such devices for soft tissue, a category encompassing some of the most common operations, including hernia, gallbladder and hysterectomy surgeries.
Intuitive Surgical, which brought its first robot to the market in 2000, dominates the field with more than 11,000 systems installed around the world. More recent entrants include Medtronic Plc, whose Hugo robot was cleared for urologic surgery in the US in 2025, and UK-based CMR Surgical, maker of a device that received its first US authorization for gallbladder operations in 2024.
J&J says Ottava takes up 30% to 50% less space than other systems. Instead of developing a device that must be positioned next to the patient, it built four robotic arms directly into the operating table. They fold down under the table when not in use.
“The table is a robot and the robot is a table,” said Rocco De Bernardis, J&J’s global president for Ottava and MedTech, during an exclusive demonstration of the device for Bloomberg at the company’s Santa Clara, California, office. “There is nothing else like this on the market.”
While the initial clearance is limited to upper abdominal operations, J&J executives said they have designed the Ottava device to be capable of performing all the major types of procedures that robotic surgery is used for today. Another trial in groin hernia surgery is currently ongoing.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。